Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
about
Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer modelA Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell InvasionThe antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo.Niclosamide is a potential therapeutic for familial adenomatosis polyposis by disrupting Axin-GSK3 interaction.Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo.Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.Pharmacological regulators of autophagy and their link with modulators of lupus diseaseTargeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid TumorsAntiinfectives targeting enzymes and the proton motive force.Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells.Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells.Cancer stem cells: a potential target for cancer therapy.Existing drugs and their application in drug discovery targeting cancer stem cells.Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.Combinatorial therapy for triple negative breast cancer using hyperstar polymer-based nanoparticles.Hallmarks of cancer stem cell metabolism.Niclosamide: Beyond an antihelminthic drug.Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line.Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancerCelecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity.A Constrained Helical Peptide Against S100A4 Inhibits Cell Motility in Tumor Cells.Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.Drug Repositioning for Effective Prostate Cancer Treatment.Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC
P2860
Q26991723-F29D0574-4E46-46B2-8C7D-00885E0D78B8Q28538542-17174325-C61A-4C8A-BAC6-596A53F78E27Q28552623-9A5CC2F4-E9E3-4C0D-8129-57EEAEE866F4Q33703068-BC03C715-E6E8-4B03-80D7-741323E5D861Q33761925-9901E12F-8CFB-4E6B-9D01-E6E874EFC3A9Q33813729-EA9423CF-C2C0-4AF5-912B-640072310B41Q34199032-955A66DB-2C63-47AE-8372-8224493D1EEBQ34402759-0720C088-56DF-417C-9058-D80F8A99ED06Q35845149-C47C5729-61E2-4AAB-B16C-8FDD6BE0F873Q36419761-254B5964-1045-4B00-8033-5DCF1EC13DB1Q36962480-2398E2E1-C575-488E-8E99-3731827811CCQ37469714-AF2C5D99-BFE5-45F8-8CFA-254C8E901D56Q37644761-33B638F3-7786-4B1F-80E2-09FB4900C62EQ38322466-842BE92A-DC52-434B-8872-4141EEB8F30CQ38373935-AC0B3C98-9623-41CF-957D-EB5F4674BB24Q38476034-F73F26A2-9218-4135-89B1-2AFB8BFCBC58Q38543730-AE9D979D-3FDA-4915-BABD-AE2BC070356FQ38598774-A72CFB31-00A6-4F6A-89F2-0460F820140AQ38799468-F3952AEA-FF7C-48A2-B7CE-D9F67E4DF9AEQ38830384-DEA9725B-8EF0-4F39-B380-BEFF597A4556Q38842974-3D873716-0DED-41F3-A488-0D5B45FD448BQ39227540-866730F3-E95D-409C-BBDD-B7842A967D3CQ40064435-ABFF8938-AFD2-43D9-BCE7-C276375470C2Q42339119-42FD2DD2-174E-43D6-B16F-AF65230F1AF6Q49271132-E17617B7-317D-4475-9307-E03DFC6EB156Q52959703-57456E4B-3CF4-4E06-A3A6-717C6F5E74C8Q55038918-01E5F93D-D98A-4DC2-87B6-07B8C6632C6DQ55254671-D0863DE8-9D6A-4DDF-A58B-AF6C7AB5CDC3Q55254924-E04045A1-8E37-4C35-A3B6-BAA5192D38B3Q58708393-83438DB8-734F-4B45-89C2-50930EB149B2
P2860
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@ast
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@en
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@nl
type
label
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@ast
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@en
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@nl
prefLabel
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@ast
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@en
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@nl
P2093
P2860
P3181
P1433
P1476
Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells
@en
P2093
Cheng-Chang Chang
Hung-Cheng Lai
Mu-Hsien Yu
Tai-Kuang Chao
Yu-Chi Wang
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0074538
P407
P577
2013-01-01T00:00:00Z